CMS seeks sickle cell gene therapy makers to participate in Medicaid drug model
The Centers for Medicare & Medicaid Services March 7 invited drug makers in the Medicaid Drug Rebate Program that make federally approved gene therapies for sickle cell disease to apply through May 1 to participate in the Cell and Gene Therapy Access Model. Announced in January, the model will negotiate rebate agreements with participating drug makers in an effort to increase access to treatments for Medicaid patients with rare and severe diseases, beginning with sickle cell disease. CMS expects states to apply this summer to participate in the voluntary model, which may also include the Children’s Health Insurance Program, depending on state and manufacturer interest.
Related News Articles
Headline
The Department of Health and Human Services Office for Civil Rights released new guidance on statutory and regulatory requirements under 42 CFR Part 2, which…
Headline
The Centers for Medicare & Medicaid Services Sept. 25 announced the launch of a new initiative measuring quality in Medicaid and the Children’s Health…
Headline
The AHA commented Sept. 21 on the Centers for Medicare & Medicaid Services’ proposed rule to implement the changes to Medicaid provider tax policies that…
Headline
The AHA July 31 provided comments to the Centers for Medicare & Medicaid Services on its interim final rule on Medicaid community engagement requirements.…
Headline
The Centers for Medicare & Medicaid Services today released a proposed rule that would update Medicaid provider tax policies included in the July 2025…
Headline
The AHA provided comments July 21 to the Centers for Medicare & Medicaid Services on its proposed rule to modify policies governing Medicaid…